Edgewood Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 44.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 216,431 shares of the company's stock after selling 172,196 shares during the quarter. Eli Lilly and Company makes up approximately 4.0% of Edgewood Management LLC's investment portfolio, making the stock its 11th largest position. Edgewood Management LLC's holdings in Eli Lilly and Company were worth $250,428,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Coastal Bridge Advisors LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $2,959,000. Birinyi Associates Inc. lifted its stake in Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company's stock worth $1,689,000 after purchasing an additional 359 shares in the last quarter. Bridges Investment Management Inc. boosted its holdings in shares of Eli Lilly and Company by 38.5% during the 3rd quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company's stock valued at $40,838,000 after purchasing an additional 9,815 shares during the last quarter. Bernicke Wealth Management Ltd. purchased a new position in shares of Eli Lilly and Company during the third quarter valued at about $5,001,000. Finally, Mosaic Family Wealth Partners LLC boosted its stake in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock valued at $4,144,000 after buying an additional 1,430 shares during the last quarter. Institutional investors own 82.53% of the company's stock.
Insider Buying and Selling at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on LLY shares. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a research note on Friday, October 30th. Argus raised their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a "buy" rating in a research note on Friday, October 30th. TD Cowen restated a "buy" rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. China Merchants Securities downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, November 12th. Finally, Cantor Fitzgerald increased their target price on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an "overweight" rating in a research note on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $1,422.00.
View Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
Eli Lilly and Company stock opened at $1,346.40 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock has a market cap of $1.27 trillion, a price-to-earnings ratio of 43.70, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The firm has a 50-day moving average of $1,268.06 and a two-hundred day moving average of $1,119.25. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. Eli Lilly and Company's quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $7.02 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 35.72 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's payout ratio is 22.46%.
Latest Eli Lilly and Company News
Here's some of the latest news about LLY:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
- Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Read More
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.